A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Participants With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in sparticipants with HER2-Abnormally Expressed locally advanced or metastatic colorectal cancer (CRC).
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Ruihua Xu, Doctor
- 電話番号:020-87343468
- メール:xurh@syscc.org.cn
研究場所
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100034
- まだ募集していません
- Peking University First Hospital
-
コンタクト:
- Shikai Wu, Doctor
- 電話番号:15810037307
- メール:Skywu4923@sina.com
-
-
Chongqing Municipality
-
Chongqing、Chongqing Municipality、中国、400016
- まだ募集していません
- The First Affiliated Hospital of Chongqing Medical University
-
コンタクト:
- Tao Zhang, Doctor
- 電話番号:13708311156
- メール:tumorzzt@163.com
-
-
Gansu
-
Lanzhou、Gansu、中国、730050
- まだ募集していません
- Gansu Provincial Tumor Hospital
-
コンタクト:
- Zhihu Li, Master
- 電話番号:18993042850
- メール:245698692@qq.com
-
-
Guangdong
-
Foshan、Guangdong、中国、528000
- まだ募集していません
- The First People's Hospital of Foshan
-
コンタクト:
- Wei Wang, Doctor
- 電話番号:18038863618
- メール:wangwei@fsyyy.com
-
Guangzhou、Guangdong、中国、510060
- 募集
- Sun Yat-sen University Cancer Center
-
コンタクト:
- Ruihua Xu, Doctor
- 電話番号:020-87343468
- メール:xurh@syscc.org.cn
-
Guangzhou、Guangdong、中国、510000
- まだ募集していません
- The Sixth Affiliated Hospital, Sun Yat-sen University
-
コンタクト:
- Yanhon Den, Doctor
- 電話番号:13925106525
- メール:dengyanh@mail.sysu.edu.cn
-
-
Guangxi
-
Nanning、Guangxi、中国、530000
- まだ募集していません
- Guangxi Zhuang Autonomous Region Cancer Hospital
-
コンタクト:
- Rong Liang, Doctor
- 電話番号:18677070811
- メール:53371159@qq.com
-
-
Guizhou
-
Zunyi、Guizhou、中国、563000
- 募集
- The Affiliated Hospital of Zunyi Medical University
-
コンタクト:
- Jiwei Wang, Doctor
- 電話番号:18013964231
- メール:zmu_wangjw@163.com
-
-
Heilongjiang
-
Harbin、Heilongjiang、中国、150000
- まだ募集していません
- Harbin Medical University Cancer Hospital
-
コンタクト:
- Tongsen Zheng, Doctor
- 電話番号:15134569619
- メール:zhengtongsen@126.com
-
コンタクト:
- Yuxian Bai, Doctor
- 電話番号:13945095085
- メール:bai_yuxian@126.com
-
Qiqihar、Heilongjiang、中国、161005
- まだ募集していません
- Qiqihar First Hospital
-
コンタクト:
- Xiyuan Sun, Doctor
- 電話番号:13945258792
- メール:sunxiyuan2004@126.com
-
-
Henan
-
Zhengzhou、Henan、中国、450000
- まだ募集していません
- Henan Cancer Hospital
-
コンタクト:
- Ying Liu, Doctor
- 電話番号:13783604602
- メール:yaya7207@126.com
-
Zhengzhou、Henan、中国、450000
- まだ募集していません
- The Third People's Hospital of Zhengzhou
-
コンタクト:
- HaiCun Wang, Master
- 電話番号:13803833783
- メール:whc1975@126.com
-
Zhengzhou、Henan、中国、450000
- まだ募集していません
- The first affiliated hospital of Zhengzhou university
-
コンタクト:
- Yongxu Jia, Doctor
- 電話番号:15237128281
- メール:fccjiayx@zzu.edu.cn
-
-
Hubei
-
Jingzhou、Hubei、中国、434099
- まだ募集していません
- Jingzhou First People's Hospital
-
コンタクト:
- Yan Hu, Master
- 電話番号:18163137369
- メール:helensparkle@163.com
-
Wuhan、Hubei、中国、430022
- まだ募集していません
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
コンタクト:
- Hongli Liu, Doctor
- 電話番号:13995680822
- メール:hongliliu@hust.edu.cn
-
-
Hunan
-
Changsha、Hunan、中国、410013
- 募集
- Hunan Cancer Hospital
-
コンタクト:
- Yi He, Doctor
- 電話番号:18692237222
- メール:heyi@hnca.org.cn
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210008
- 募集
- Nanjing Drum Tower Hospital
-
コンタクト:
- Yudong Qiu, Doctor
- 電話番号:13951806490
- メール:yudongqiu510@163.com
-
Nanjing、Jiangsu、中国、210009
- 募集
- Zhongda Hospital Southeast University
-
コンタクト:
- CaiLian Wang, Doctor
- 電話番号:13851756378
- メール:wangcailian65@hotmail.com
-
Nanjing、Jiangsu、中国、210000
- まだ募集していません
- Jiangsu Provincial Cancer Hospital
-
コンタクト:
- Yuanhua Liu, Doctor
- 電話番号:13305180356
- メール:yuanhualiu02@hotmail.com
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330000
- まだ募集していません
- Jiangxi Provincal People's Hospital
-
コンタクト:
- Weirong Yao, Doctor
- 電話番号:13907002901
- メール:13907002901@126.com
-
-
Jilin
-
Changchun、Jilin、中国、130021
- まだ募集していません
- Jilin Cancer Hospital
-
コンタクト:
- Hongxia Cui, Master
- 電話番号:13504436090
- メール:2503074283@qq.com
-
Changchun、Jilin、中国、130021
- まだ募集していません
- The first hospital of Jilin University
-
コンタクト:
- Tingting Liang, Doctor
- 電話番号:15804303776
- メール:liangting2006@163.com
-
-
Liaoning
-
Shenyang、Liaoning、中国、110000
- 募集
- Liaoning Cancer Hospital & Institute
-
コンタクト:
- Jingdong Zhang, Doctor
- 電話番号:18040007878
- メール:13804027878@163.com
-
-
Shaanxi
-
Xi'an、Shaanxi、中国、710000
- まだ募集していません
- The First Affiliated Hospital of Xi'an Jiaotong University Medical College
-
コンタクト:
- Aili Suo, Doctor
- 電話番号:18991232561
- メール:Ailisuo@mail.xjtu.edu.cn
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200127
- 募集
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
-
コンタクト:
- XiuYing Xiao, Doctor
- 電話番号:13564579313
- メール:xiaoxiuying2002@163.com
-
-
Shanxi
-
Xi’an、Shanxi、中国、710000
- まだ募集していません
- The Second Affiliated Hospital of Air Force Medical University
-
コンタクト:
- Haichuan Su, Doctor
- 電話番号:18629190366
- メール:cntdgcp@163.com
-
Xi’an、Shanxi、中国、710000
- まだ募集していません
- The First Affiliated Hospital of Air Force Medical University
-
コンタクト:
- Yongzhan Nie, Doctor
- 電話番号:15091520001
- メール:nieyongzhan@qq.com
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、300202
- 募集
- Tianjin Medical University Cancer Institute & Hospital
-
コンタクト:
- Zhanyu Pan, Master
- 電話番号:18622221256
- メール:tjpanzy@126.com
-
Tianjin、Tianjin Municipality、中国、300121
- まだ募集していません
- Tianjin Union Medical Center
-
コンタクト:
- Mingqing Zhang, Doctor
- 電話番号:15122875158
- メール:zmq1003@163.com
-
-
Xinjiang
-
Ürümqi、Xinjiang、中国、830054
- まだ募集していません
- Xinjiang Medical University Affiliated Tumor Hospital
-
コンタクト:
- YanLi Qu, Master
- 電話番号:18160627963
- メール:quyanli73@163.com
-
-
Zhejiang
-
Lishui、Zhejiang、中国、323000
- 募集
- Lishui Municipal Central Hospital
-
コンタクト:
- Yanru Xie, Master
- 電話番号:13567615770
- メール:43437677@qq.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participants voluntarily participate in this study, sign the informed consent form, and have good compliance
- Age: 18-75 years (including the boundary when signing the informed consent form)
- Eastern Cooperative Oncology Group (ECOG) score: 0-1
- Expected survival of more than 3 months
- Unresectable locally advanced or metastatic colorectal cancer diagnosed by histopathology/cytology
- HER2-Abnormally Expressed tested
- Presence of at least one measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- Participants should agree to use contraception during the study and for 6 months after the end
Exclusion Criteria:
- Participants with previously confirmed Microsatellite Instability Microsatellite Instability-High Deficient Mismatch Repair (MSI-H/dMMR)
- Presence of conditions affecting intravenous, venous blood sampling, or multiple factors affecting oral medications
- Active inflammatory bowel disease within 28 days prior to first dose
- Other malignancies within 5 years prior to the first dose or currently suffering from other malignancies
- Unresolved toxicity greater than CTCAE Grade 1 due to any prior therapy
- Major surgical treatment, significant traumatic injury within 28 days prior to the first dose or anticipation of major surgery during study treatment
- Had wounds or fractures that had not been healed for a long time
- Cerebrovascular accident, deep venous thrombosis and pulmonary embolism within 6 months prior to the first dose
- Patients with a history of psychotropic substance abuse who cannot quit or have mental disorders
- Participants with any severe and/or uncontrolled disease
- Known tumor-related carcinomatous meningitis with symptoms of brain metastases or symptom control for less than 4 weeks
- Patients with imaging suggestive of tumor invasion of major blood vessels or fatal massive hemorrhage due to tumor rupture or invasion of major blood vessels judged by the investigator to be very likely to occur during the study
- Failure to control serous effusions requiring repeated drainage
- Local radiotherapy or 4. Bone marrow irradiation > 30% for bone metastasis before the first medication
- Known tumor-related spinal cord compression, weight-bearing bone pathological fracture, extensive bone metastasis, or uncontrollable tumor bone metastasis-related pain
- Patients who have received chemotherapy, targeted therapy, immunotherapy or other systemic anti-tumor drug therapy before the first medication;
- Received Chinese patent medicine treatment with anti-tumor indications in the package insert of National Medical Products Administration (NMPA) approved drugs before study treatment
- History of live attenuated vaccination before the first dose or planned live attenuated vaccination during the study;
- Previous history of severe allergy of unknown origin
- According to the investigator's judgment, there are concomitant diseases that seriously endanger the participants' safety or affect the completion of the study, or the participant is considered unsuitable for other reasons
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:TQB2930 injection +chemotherapy + Bevacizumab injection
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. Bevacizumab blocks VEGF binding to receptors and inhibits tumor angiogenesis. |
|
アクティブコンパレータ:TQB2930 injection +chemotherapy
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Recommended Phase 2 Dose
時間枠:Baseline up to 21 days
|
It refers to the safe and effective dose range that can be used for phase II study determined through phase I clinical trial. |
Baseline up to 21 days
|
|
Adverse event (AE)
時間枠:From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
Incidence and severity of adverse events. |
From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
|
Objective Response Rate
時間枠:Baseline up to 24 months
|
The proportion of participants achieving complete response and partial response among the total evaluable cases. |
Baseline up to 24 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Half-life
時間枠:Baseline up to 24 months
|
The time it takes for the concentration of a drug in the body (usually the plasma concentration) to decrease to half of its initial value. |
Baseline up to 24 months
|
|
Plasma concentration-time profiles
時間枠:Baseline up to 24 months
|
Total area covered under the curve plotted with time as X-axis and plasma concentration as Y-axis. |
Baseline up to 24 months
|
|
Apparent clearance
時間枠:Baseline up to 24 months
|
The rate at which the drug is cleared from the body. |
Baseline up to 24 months
|
|
Apparent terminal volume of distribution
時間枠:Baseline up to 24 months
|
Describe the drug distribution in the body. |
Baseline up to 24 months
|
|
Trough plasma concentration
時間枠:Baseline up to 24 months
|
Minimum plasma drug concentration level at the end of the dosing interval (before the next dosing). |
Baseline up to 24 months
|
|
Disease Control Rate
時間枠:Baseline up to 24 months
|
The percentage of participants with a complete response, partial response, or stable disease as determined by RECIST 1.1. |
Baseline up to 24 months
|
|
Duration Of Response
時間枠:Baseline up to 24 months
|
The time from the first assessment of the tumor as a complete response or partial response to the first occurrence of disease progression or death from any cause. |
Baseline up to 24 months
|
|
Progression Free Survival
時間枠:Baseline up to 24 months
|
Progression Free Survival (PFS) is defined as the length of time from the start of treatment until the disease progresses or the patient dies from any cause. |
Baseline up to 24 months
|
|
Overall Survival
時間枠:Baseline up to 24 months
|
The time from the start of initial treatment to death from any cause. |
Baseline up to 24 months
|
|
Anti-Drug Antibodies (ADA) incidence
時間枠:Baseline up to 24 months
|
Proportion of anti-drug antibody produced in the population of patients using the drug. |
Baseline up to 24 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。